Mission Therapeutics divests AKI asset MTX652 to Dimerix for up to $292m
Mission Therapeutics has divested MTX652, a Phase 2-ready oral USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited in a deal worth up to US$292 million. The transaction combines upfront and milestone payments with double-digit tiered royalties on global net sales, and allows Mission to redeploy non-dilutive capital into its lead CNS asset, MTX325, currently in Phase 1 for Parkinson's disease.
MTX652 is a selective, orally administered inhibitor of USP30, a mitochondrial enzyme that suppresses the clearance of damaged mitochondria. By blocking USP30, the compound is designed to restore mitochondrial quality control in injured kidney cells following ischaemia, toxin exposure or sepsis. Critically, the asset comes with an open IND and an FDA-approved Phase 2 protocol already in place, meaning Dimerix can move directly into a pivotal-stage study without repeating the regulatory groundwork.
The deal
Anker Lundemose, Executive Director at Mission Therapeutics, described the divestment as providing "an expedited path to patients for MTX652" while simultaneously strengthening Mission's financial position. Dimerix chief executive Nina Webster framed the acquisition as complementary to the company's existing Phase 3 ACTION3 programme in Focal Segmental Glomerulosclerosis, noting that it "broadens our development footprint across the kidney disease continuum, from acute injury through to chronic disease."
Guggenheim Securities advised Mission on the transaction and Cooley LLP acted as legal counsel.
For Mission, the logic is straightforward: the USP30 platform has generated two clinically validated candidates, and rather than stretching a Cambridge-based team across both nephrology and neurology, the company is concentrating resources on the area where it believes it can best compete. Proof-of-mechanism biomarker and imaging data from the MTX325 Parkinson's programme are expected in late 2027, giving investors a defined near-term readout window. Composition-of-matter IP on MTX325 extends through 2041, providing a long commercial runway if Phase 2 data are positive.
Market context
The AKI space has historically attracted limited pharmaceutical investment relative to chronic kidney disease, in part because the acute setting makes trial design and commercial models harder to execute. However, interest has grown as the link between AKI episodes and longer-term chronic kidney disease progression has become better characterised. Dimerix, with its established renal network and an existing late-stage FSGS programme, is arguably better placed than a CNS-focused shop to navigate the nephrology payer and key opinion leader landscape.
Mission's backing from Pfizer Venture Investments, Roche Venture Fund and Sofinnova Partners indicates institutional confidence in the USP30 mechanism more broadly. Those investors will now be hoping that shedding the AKI asset accelerates MTX325 toward the proof-of-concept data that would support a larger Series financing or a partnering deal in Parkinson's, where several large pharma groups are actively seeking disease-modifying approaches beyond alpha-synuclein antibodies. The mitophagy angle, centred on restoring neuronal health rather than targeting a single protein, positions MTX325 in a mechanistically distinct corner of a crowded field, though clinical validation of that hypothesis in patients remains the pivotal test.